[
  {
    "ts": null,
    "headline": "How major US stock indexes fared Thursday, 12/11/2025",
    "summary": "The Dow Jones Industrial Average jumped 646 points and topped its own record set last month. Weakness for AI-related stocks, though, weighed on the Nasdaq composite, which fell 0.3%. Gains for Eli Lilly, banks and smaller stocks helped offset a steep drop for Oracle, whose plans for increased spending on AI surprised analysts.",
    "url": "https://finnhub.io/api/news?id=03398e5e4fdb4b823023f749573da7e3067f1285c181aaf1308bbcb67cceb942",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765488203,
      "headline": "How major US stock indexes fared Thursday, 12/11/2025",
      "id": 137762296,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average jumped 646 points and topped its own record set last month. Weakness for AI-related stocks, though, weighed on the Nasdaq composite, which fell 0.3%. Gains for Eli Lilly, banks and smaller stocks helped offset a steep drop for Oracle, whose plans for increased spending on AI surprised analysts.",
      "url": "https://finnhub.io/api/news?id=03398e5e4fdb4b823023f749573da7e3067f1285c181aaf1308bbcb67cceb942"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 0.9% and the Sta",
    "url": "https://finnhub.io/api/news?id=22f837f5551eb9c63aa7c3b3b2d97d1927fe8bec24dd1b99540870ac46c5821a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765486727,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 137762297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 0.9% and the Sta",
      "url": "https://finnhub.io/api/news?id=22f837f5551eb9c63aa7c3b3b2d97d1927fe8bec24dd1b99540870ac46c5821a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Says Trial of Weight-Loss Drug Retatrutide Yields Encouraging Results",
    "summary": "Eli Lilly (LLY) said Thursday that a late-stage trial of retatrutide, its injectable weight-loss dru",
    "url": "https://finnhub.io/api/news?id=b1d16a0eac721a914953f30155a20b50d8f6102054a38fd443d63bfb34849c44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765481127,
      "headline": "Eli Lilly Says Trial of Weight-Loss Drug Retatrutide Yields Encouraging Results",
      "id": 137762298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) said Thursday that a late-stage trial of retatrutide, its injectable weight-loss dru",
      "url": "https://finnhub.io/api/news?id=b1d16a0eac721a914953f30155a20b50d8f6102054a38fd443d63bfb34849c44"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Thursday Afternoon",
    "summary": "Health care stocks rose Thursday afternoon, with the NYSE Health Care Index and the State Street Hea",
    "url": "https://finnhub.io/api/news?id=bfcafc9ec8780493ba6315279d6c8f78db8d1f9d67a6d4376a99816c114e8cee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765478729,
      "headline": "Sector Update: Health Care Stocks Rise Thursday Afternoon",
      "id": 137760427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose Thursday afternoon, with the NYSE Health Care Index and the State Street Hea",
      "url": "https://finnhub.io/api/news?id=bfcafc9ec8780493ba6315279d6c8f78db8d1f9d67a6d4376a99816c114e8cee"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 retreats from record, Nasdaq falls more than 1% as rotation out of tech continues, led by Broadcom: Live updates",
    "summary": "Investors on Thursday poured into cyclical stocks that are considered more sensitive to the economy, a day after the Fed cut rates for the third time this year.",
    "url": "https://finnhub.io/api/news?id=3438230ad2ec2ca63a92544372dfceab29a013baceff6fb067050b60ebcacc82",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765476225,
      "headline": "S&P 500 retreats from record, Nasdaq falls more than 1% as rotation out of tech continues, led by Broadcom: Live updates",
      "id": 137768868,
      "image": "https://image.cnbcfm.com/api/v1/image/108240924-1765489849116-gettyimages-2251443983-anotherday161738358_xwgo9crb.jpeg?v=1765489975&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Investors on Thursday poured into cyclical stocks that are considered more sensitive to the economy, a day after the Fed cut rates for the third time this year.",
      "url": "https://finnhub.io/api/news?id=3438230ad2ec2ca63a92544372dfceab29a013baceff6fb067050b60ebcacc82"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises After New Obesity Drug Crushes Phase 3 Goals",
    "summary": "Lilly Boosts Lead in Weight-Loss Race as New Drug Hits All Endpoints",
    "url": "https://finnhub.io/api/news?id=af56556e1713bb969ddc80e41c7bc2ee3e3d22f11cabb3af4d05ada19b1bfaec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765473595,
      "headline": "Eli Lilly Stock Rises After New Obesity Drug Crushes Phase 3 Goals",
      "id": 137759739,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly Boosts Lead in Weight-Loss Race as New Drug Hits All Endpoints",
      "url": "https://finnhub.io/api/news?id=af56556e1713bb969ddc80e41c7bc2ee3e3d22f11cabb3af4d05ada19b1bfaec"
    }
  },
  {
    "ts": null,
    "headline": "Missed Ozempic? Lilly's Next Drug Could Be Even Bigger",
    "summary": "Retatrutide just delivered over 23% weight loss in trials, raising the stakes in the $100B obesity race.",
    "url": "https://finnhub.io/api/news?id=c54fc2ee66b631778917894d09465dfc69a0d860b21d9d6605213cc571a40df9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765473064,
      "headline": "Missed Ozempic? Lilly's Next Drug Could Be Even Bigger",
      "id": 137759740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Retatrutide just delivered over 23% weight loss in trials, raising the stakes in the $100B obesity race.",
      "url": "https://finnhub.io/api/news?id=c54fc2ee66b631778917894d09465dfc69a0d860b21d9d6605213cc571a40df9"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend ETFs to Buy and Hold for Life if the Market Crashes",
    "summary": "Dividend ETFs may be the best investment you can make today. The iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT), iShares Global Consumer Staples ETF (NYSEARCA:KXI), and iShares US Pharmaceuticals ETF (NYSEARCA:IHE) are worth considering first. These ETFs can help you ride through a near-term market crash by providing ballast while providing you with income to ... 3 Dividend ETFs to Buy and Hold for Life if the Market Crashes",
    "url": "https://finnhub.io/api/news?id=65b7244e319433aeca0c55b90652e65a14e45e631d664fc6d650ab14893f2848",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765472801,
      "headline": "3 Dividend ETFs to Buy and Hold for Life if the Market Crashes",
      "id": 137759741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Dividend ETFs may be the best investment you can make today. The iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT), iShares Global Consumer Staples ETF (NYSEARCA:KXI), and iShares US Pharmaceuticals ETF (NYSEARCA:IHE) are worth considering first. These ETFs can help you ride through a near-term market crash by providing ballast while providing you with income to ... 3 Dividend ETFs to Buy and Hold for Life if the Market Crashes",
      "url": "https://finnhub.io/api/news?id=65b7244e319433aeca0c55b90652e65a14e45e631d664fc6d650ab14893f2848"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Is Up, What You Need To Know",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the morning session after the company announced highly positive Phase 3 trial results for its next-generation weight loss candidate, retatrutide.",
    "url": "https://finnhub.io/api/news?id=94115fdee04fb6cd640630d2b4f23d884a9e71635d6e2f709a6898659199f3d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765472444,
      "headline": "Eli Lilly (LLY) Stock Is Up, What You Need To Know",
      "id": 137759742,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the morning session after the company announced highly positive Phase 3 trial results for its next-generation weight loss candidate, retatrutide.",
      "url": "https://finnhub.io/api/news?id=94115fdee04fb6cd640630d2b4f23d884a9e71635d6e2f709a6898659199f3d7"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Oracle Shares Tumble After Revenue Miss; Lilly's Next-Gen Weight-Loss Drug Hits Primary Endpoints",
    "summary": "The Dow Jones Industrial Average was down, while the S&P 500 and Nasdaq Composite were also lower in",
    "url": "https://finnhub.io/api/news?id=195a92758faa8fd5332aaa96d597a325473383a533ab9da4c18d3d3b231c93dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765471004,
      "headline": "Top Midday Stories: Oracle Shares Tumble After Revenue Miss; Lilly's Next-Gen Weight-Loss Drug Hits Primary Endpoints",
      "id": 137758715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average was down, while the S&P 500 and Nasdaq Composite were also lower in",
      "url": "https://finnhub.io/api/news?id=195a92758faa8fd5332aaa96d597a325473383a533ab9da4c18d3d3b231c93dc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.",
    "summary": "The company said some patients had dropped out of the trial because they felt they were losing too much weight.",
    "url": "https://finnhub.io/api/news?id=577cfcfa628c9c3b0d649a0ce5321c8e9aa8ed2a1caf5130f86c2d03bb0a0538",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765470180,
      "headline": "Eli Lilly’s Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.",
      "id": 137759743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company said some patients had dropped out of the trial because they felt they were losing too much weight.",
      "url": "https://finnhub.io/api/news?id=577cfcfa628c9c3b0d649a0ce5321c8e9aa8ed2a1caf5130f86c2d03bb0a0538"
    }
  },
  {
    "ts": null,
    "headline": "Abivax: \"Strong Buy\" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026",
    "summary": "Abivax receives a \"Strong Buy\" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis. Read the latest analysis on the stock here.",
    "url": "https://finnhub.io/api/news?id=21af76cd89c1ec0c572fbf772c5657570e14d5982ebb382b7259d7f7eca708e9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765469463,
      "headline": "Abivax: \"Strong Buy\" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026",
      "id": 137762180,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241458915/image_2241458915.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Abivax receives a \"Strong Buy\" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis. Read the latest analysis on the stock here.",
      "url": "https://finnhub.io/api/news?id=21af76cd89c1ec0c572fbf772c5657570e14d5982ebb382b7259d7f7eca708e9"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday: Oracle, Broadcom, Nvidia, Gemini",
    "summary": "↘️ Oracle (ORCL): The software maker's quarterly capital spending soared passed expectations, fueling fears of overexpenditure on the AI data center buildout. Shares dropped 11% in premarket trading. ↘️ AMD (AMD), Nvidia (NVDA): Other artificial-intelligence stocks dropped in the wake of Oracle's earnings.",
    "url": "https://finnhub.io/api/news?id=756159d902b37b82bdab446dc19549a1ae41d89268d4978666d7a69e012cae11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765451933,
      "headline": "Stocks to Watch Thursday: Oracle, Broadcom, Nvidia, Gemini",
      "id": 137756843,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↘️ Oracle (ORCL): The software maker's quarterly capital spending soared passed expectations, fueling fears of overexpenditure on the AI data center buildout. Shares dropped 11% in premarket trading. ↘️ AMD (AMD), Nvidia (NVDA): Other artificial-intelligence stocks dropped in the wake of Oracle's earnings.",
      "url": "https://finnhub.io/api/news?id=756159d902b37b82bdab446dc19549a1ae41d89268d4978666d7a69e012cae11"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss",
    "summary": "Eli Lilly is putting the \"obesity field on notice again,\" an analyst said Thursday after its next-gen delivered 28.7% weight loss.",
    "url": "https://finnhub.io/api/news?id=59519a47b5704dac830391fc801aaccc6fb0bc3bf2281e7e13c513cae0dbaf27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765467695,
      "headline": "Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss",
      "id": 137757877,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is putting the \"obesity field on notice again,\" an analyst said Thursday after its next-gen delivered 28.7% weight loss.",
      "url": "https://finnhub.io/api/news?id=59519a47b5704dac830391fc801aaccc6fb0bc3bf2281e7e13c513cae0dbaf27"
    }
  },
  {
    "ts": null,
    "headline": "Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III",
    "summary": "RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.",
    "url": "https://finnhub.io/api/news?id=35f2307e3ec60ab022764fdccd28141be15b573b6e58273d874174daa9314a3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765467000,
      "headline": "Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III",
      "id": 137759744,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.",
      "url": "https://finnhub.io/api/news?id=35f2307e3ec60ab022764fdccd28141be15b573b6e58273d874174daa9314a3a"
    }
  },
  {
    "ts": null,
    "headline": "Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?",
    "summary": "LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.",
    "url": "https://finnhub.io/api/news?id=5b2a3d54b53e59f3fe4759ad5aefaf3d8766c84ad460e0a5adb8acd34b60c3d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765466580,
      "headline": "Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?",
      "id": 137759745,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.",
      "url": "https://finnhub.io/api/news?id=5b2a3d54b53e59f3fe4759ad5aefaf3d8766c84ad460e0a5adb8acd34b60c3d2"
    }
  },
  {
    "ts": null,
    "headline": "WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?",
    "summary": "Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.",
    "url": "https://finnhub.io/api/news?id=fa54eda3eb20834ec3cebb8fe0c8fb30a551c7cd339c87ee16ce4d5f933f9ca8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765466100,
      "headline": "WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?",
      "id": 137759746,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.",
      "url": "https://finnhub.io/api/news?id=fa54eda3eb20834ec3cebb8fe0c8fb30a551c7cd339c87ee16ce4d5f933f9ca8"
    }
  },
  {
    "ts": null,
    "headline": "New Lilly Shot Reduces Body Weight by 23% in Study",
    "summary": "A next-generation obesity shot from Eli Lilly helped patients lose nearly a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. Madison Muller reports on Bloomberg Television.",
    "url": "https://finnhub.io/api/news?id=31ccbc8a7a68490017864fe64fa88338457ba6cc9c7fc0179bcd6489ede57227",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765463742,
      "headline": "New Lilly Shot Reduces Body Weight by 23% in Study",
      "id": 137757878,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A next-generation obesity shot from Eli Lilly helped patients lose nearly a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. Madison Muller reports on Bloomberg Television.",
      "url": "https://finnhub.io/api/news?id=31ccbc8a7a68490017864fe64fa88338457ba6cc9c7fc0179bcd6489ede57227"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's obesity drug trial results, Coca-Cola names next CEO",
    "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including the results of Eli Lilly's (LLY) latest obesity drug test, Coca-Cola (KO) named Henrique Braun as the next CEO after current chief executive James Quincey steps down from the role at the end of March 2026, and Gemini Space Station (GEMI) receiving approval to operate as a predictions market by the Commodity Futures Trading Commission (CFTC). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=9aab0ecba6ab84a4e9011ba14b14ae491b8c679d2b304ac8f80737bf645eddef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765463551,
      "headline": "Eli Lilly's obesity drug trial results, Coca-Cola names next CEO",
      "id": 137757879,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including the results of Eli Lilly's (LLY) latest obesity drug test, Coca-Cola (KO) named Henrique Braun as the next CEO after current chief executive James Quincey steps down from the role at the end of March 2026, and Gemini Space Station (GEMI) receiving approval to operate as a predictions market by the Commodity Futures Trading Commission (CFTC). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=9aab0ecba6ab84a4e9011ba14b14ae491b8c679d2b304ac8f80737bf645eddef"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Reports Dramatic Weight Loss in Next-Gen Obesity-Drug Trial",
    "summary": "Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial.",
    "url": "https://finnhub.io/api/news?id=5a47cda9d763fbafcaecadce6956e84a38fb1810471a103d7cddfcf9155d9188",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765463400,
      "headline": "Eli Lilly Reports Dramatic Weight Loss in Next-Gen Obesity-Drug Trial",
      "id": 137757880,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial.",
      "url": "https://finnhub.io/api/news?id=5a47cda9d763fbafcaecadce6956e84a38fb1810471a103d7cddfcf9155d9188"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Reports Strong Late-Stage Results for Next-Generation Obesity Drug Retatrutide",
    "summary": "This article first appeared on GuruFocus.  Eli Lilly (LLY, Financials) reported late-stage results showing its next-generation obesity drug retatrutide produced the strongest weight loss seen so far in a phase-three trial and reduced knee pain in patients with obesity and osteoarthritis.  The highest dose led to 23.7% average weight loss at 68 weeks when including all participants and 28.7% among those who completed treatment.",
    "url": "https://finnhub.io/api/news?id=ca0ab4721359255cc483cf4213d697ef4bed559f4f0e453119d04644e04d5b6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765463168,
      "headline": "Eli Lilly Reports Strong Late-Stage Results for Next-Generation Obesity Drug Retatrutide",
      "id": 137757881,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This article first appeared on GuruFocus.  Eli Lilly (LLY, Financials) reported late-stage results showing its next-generation obesity drug retatrutide produced the strongest weight loss seen so far in a phase-three trial and reduced knee pain in patients with obesity and osteoarthritis.  The highest dose led to 23.7% average weight loss at 68 weeks when including all participants and 28.7% among those who completed treatment.",
      "url": "https://finnhub.io/api/news?id=ca0ab4721359255cc483cf4213d697ef4bed559f4f0e453119d04644e04d5b6a"
    }
  },
  {
    "ts": null,
    "headline": "GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?",
    "summary": "GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.",
    "url": "https://finnhub.io/api/news?id=fa824c73af7e408e8ee311994eaec1288b2a5adb3fef507aceb50cd42ff41593",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765462320,
      "headline": "GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?",
      "id": 137758751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.",
      "url": "https://finnhub.io/api/news?id=fa824c73af7e408e8ee311994eaec1288b2a5adb3fef507aceb50cd42ff41593"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: OpenAI Gets Mickey, Nemo, Hulk And C-3PO",
    "summary": "Disney is making a $1B investment in OpenAI and signed a sweeping three-year licensing deal that allows OpenAIâs video model Sora to generate content using Disneyâs intellectual properties.",
    "url": "https://finnhub.io/api/news?id=0f1579c0158bfc50c45729a9e68956f2a55eab6adb5f12863d7adc1539342ed1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765461247,
      "headline": "Wall Street Lunch: OpenAI Gets Mickey, Nemo, Hulk And C-3PO",
      "id": 137760319,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195318556/image_2195318556.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Disney is making a $1B investment in OpenAI and signed a sweeping three-year licensing deal that allows OpenAIâs video model Sora to generate content using Disneyâs intellectual properties.",
      "url": "https://finnhub.io/api/news?id=0f1579c0158bfc50c45729a9e68956f2a55eab6adb5f12863d7adc1539342ed1"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Reports Positive Results in Next-Gen Obesity Drug Trial",
    "summary": "Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial.",
    "url": "https://finnhub.io/api/news?id=5b0d2ca1e9284b02abbb5926a67f747c0c12b015bdfb6abc365cf0729b12351b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765459980,
      "headline": "Lilly Reports Positive Results in Next-Gen Obesity Drug Trial",
      "id": 137757882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial.",
      "url": "https://finnhub.io/api/news?id=5b0d2ca1e9284b02abbb5926a67f747c0c12b015bdfb6abc365cf0729b12351b"
    }
  },
  {
    "ts": null,
    "headline": "Crux Adds Obesity Management Medicine to its Newly Launched Employer Benefit Platform",
    "summary": "MCLEAN, Va., December 11, 2025--Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved medications, today announced Eli Lilly and Company’s Zepbound® will be the first medication available on its platform.",
    "url": "https://finnhub.io/api/news?id=246354813cee13cd61848de6c9e577e759bd9ea89108bf6d04feca246c93e4d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765458000,
      "headline": "Crux Adds Obesity Management Medicine to its Newly Launched Employer Benefit Platform",
      "id": 137757883,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MCLEAN, Va., December 11, 2025--Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved medications, today announced Eli Lilly and Company’s Zepbound® will be the first medication available on its platform.",
      "url": "https://finnhub.io/api/news?id=246354813cee13cd61848de6c9e577e759bd9ea89108bf6d04feca246c93e4d7"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Rise, Techs Pare Losses; Oracle Dives On AI Spending",
    "summary": "Futures reversed higher and techs pared losses though Oracle dived on AI spending fears. GE Vernova, Palantir made bullish moves Wednesday in a Fed-led rally.",
    "url": "https://finnhub.io/api/news?id=4d8a905d1003f7a0d136f8e3dd0268a6f96ea2d6f457738c92a31edc4ef57e98",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765457434,
      "headline": "Dow Jones Futures Rise, Techs Pare Losses; Oracle Dives On AI Spending",
      "id": 137756834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Futures reversed higher and techs pared losses though Oracle dived on AI spending fears. GE Vernova, Palantir made bullish moves Wednesday in a Fed-led rally.",
      "url": "https://finnhub.io/api/news?id=4d8a905d1003f7a0d136f8e3dd0268a6f96ea2d6f457738c92a31edc4ef57e98"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7%",
    "summary": "Eli Lily rose above a key level after saying its experimental obesity treatment delivered 23.7% weight loss in a late-stage trial.",
    "url": "https://finnhub.io/api/news?id=5ca8513a6495071b493fe6db21b3855f7ae7c0254cb3c058cf2e2847b8d2301a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765456680,
      "headline": "Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7%",
      "id": 137756912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lily rose above a key level after saying its experimental obesity treatment delivered 23.7% weight loss in a late-stage trial.",
      "url": "https://finnhub.io/api/news?id=5ca8513a6495071b493fe6db21b3855f7ae7c0254cb3c058cf2e2847b8d2301a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly stock climbs after retatrutide delivers massive weight loss in trial",
    "summary": "Investing.com -- Eli Lilly (NYSE:LLY) stock rose 3% in premarket trading Thursday after the company’s experimental triple agonist drug retatrutide showed impressive weight loss results and significant osteoarthritis pain relief in its first successful Phase 3 trial.",
    "url": "https://finnhub.io/api/news?id=c9af8f765e25fba46e4e9a013a965889b902fa693c54fa64b81affbb6a7f6a49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765456113,
      "headline": "Eli Lilly stock climbs after retatrutide delivers massive weight loss in trial",
      "id": 137756914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Eli Lilly (NYSE:LLY) stock rose 3% in premarket trading Thursday after the company’s experimental triple agonist drug retatrutide showed impressive weight loss results and significant osteoarthritis pain relief in its first successful Phase 3 trial.",
      "url": "https://finnhub.io/api/news?id=c9af8f765e25fba46e4e9a013a965889b902fa693c54fa64b81affbb6a7f6a49"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves midday: Oracle, Vail Resorts, GE Vernova, Brinks, Ciena & more",
    "summary": "These are some of the stocks posting the largest moves midday.",
    "url": "https://finnhub.io/api/news?id=c5cf90dfea3051aecbc0c8099436fabcedf62f9d68b37563a5e6e12be47f59ab",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765455567,
      "headline": "Stocks making the biggest moves midday: Oracle, Vail Resorts, GE Vernova, Brinks, Ciena & more",
      "id": 137759239,
      "image": "https://image.cnbcfm.com/api/v1/image/103703377-GettyImages-109820993.jpg?v=1765472332&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "These are some of the stocks posting the largest moves midday.",
      "url": "https://finnhub.io/api/news?id=c5cf90dfea3051aecbc0c8099436fabcedf62f9d68b37563a5e6e12be47f59ab"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of the two highest investigational doses of retatrutide, a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity. In this global registration trial, where 84.0% of participants had a baseline BM",
    "url": "https://finnhub.io/api/news?id=46c6af7c36deb8085fd99afcdd6072528ba2c32a08e5b353feb91e06dacdb781",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765453500,
      "headline": "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial",
      "id": 137756915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of the two highest investigational doses of retatrutide, a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity. In this global registration trial, where 84.0% of participants had a baseline BM",
      "url": "https://finnhub.io/api/news?id=46c6af7c36deb8085fd99afcdd6072528ba2c32a08e5b353feb91e06dacdb781"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to build $6B weight-loss drug factory in Alabama",
    "summary": "This is the third of four planned U.S. manufacturing sites the pharmaceutical giant has unveiled this year, set to bring 450 factory jobs to the Huntsville area.",
    "url": "https://finnhub.io/api/news?id=243b1f80f6dd3d8cf5e2ec7c65b38a2348c9aaaaf632d582eeb1177793fe50e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765452540,
      "headline": "Lilly to build $6B weight-loss drug factory in Alabama",
      "id": 137758752,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This is the third of four planned U.S. manufacturing sites the pharmaceutical giant has unveiled this year, set to bring 450 factory jobs to the Huntsville area.",
      "url": "https://finnhub.io/api/news?id=243b1f80f6dd3d8cf5e2ec7c65b38a2348c9aaaaf632d582eeb1177793fe50e3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Retatrutide Justifies Hype With Best Weight Loss Data Yet - I'm Sold",
    "summary": "Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics. Click for this LLY update.",
    "url": "https://finnhub.io/api/news?id=36edea8f03192210963b94aed3463ce604768bcef3f14fdc804a47e721ebfef8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765450634,
      "headline": "Eli Lilly: Retatrutide Justifies Hype With Best Weight Loss Data Yet - I'm Sold",
      "id": 137758367,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189405678/image_2189405678.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics. Click for this LLY update.",
      "url": "https://finnhub.io/api/news?id=36edea8f03192210963b94aed3463ce604768bcef3f14fdc804a47e721ebfef8"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s three-pronged drug puts obesity field ‘on notice’",
    "summary": "Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar” for future obesity drug competitors, one analyst wrote.",
    "url": "https://finnhub.io/api/news?id=57952b67cd8a7a0b9a7b36fc60dc8b167103cb43dbcba49e181d93712d2dc714",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765450560,
      "headline": "Lilly’s three-pronged drug puts obesity field ‘on notice’",
      "id": 137758753,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar” for future obesity drug competitors, one analyst wrote.",
      "url": "https://finnhub.io/api/news?id=57952b67cd8a7a0b9a7b36fc60dc8b167103cb43dbcba49e181d93712d2dc714"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Sector Outlook For 2026: Sell Technology, Buy Healthcare",
    "summary": "Discover why a 2026 recession may trigger an AI bubble burst, impacting tech stocks, and learn why health care could outperform.",
    "url": "https://finnhub.io/api/news?id=3933c2e8c96f8db0f69fc02eb97df07c7b2d2039d1b2304ff6c3dec5af8862e2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765447200,
      "headline": "S&P 500 Sector Outlook For 2026: Sell Technology, Buy Healthcare",
      "id": 137757606,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2225310528/image_2225310528.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why a 2026 recession may trigger an AI bubble burst, impacting tech stocks, and learn why health care could outperform.",
      "url": "https://finnhub.io/api/news?id=3933c2e8c96f8db0f69fc02eb97df07c7b2d2039d1b2304ff6c3dec5af8862e2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Mounjaro Added to China’s National Health Insurance for Diabetes",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for the Long Term. Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health insurance program starting January 1, the National Healthcare Security Administration said in a notice on December 8. Analysts say that the move […]",
    "url": "https://finnhub.io/api/news?id=f4cb7181f0fd65b6803837574173bef9ae81879907a841c8e7bad6af80f990a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765439545,
      "headline": "Eli Lilly’s Mounjaro Added to China’s National Health Insurance for Diabetes",
      "id": 137755830,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for the Long Term. Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health insurance program starting January 1, the National Healthcare Security Administration said in a notice on December 8. Analysts say that the move […]",
      "url": "https://finnhub.io/api/news?id=f4cb7181f0fd65b6803837574173bef9ae81879907a841c8e7bad6af80f990a7"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves premarket: Oracle, Oxford Industries, Adobe, Gemini Space Station & more",
    "summary": "These are the stocks posting the largest moves in early trading.",
    "url": "https://finnhub.io/api/news?id=acb3d6f743f2fe1124fa13f9b32b4b64e62f2e1b326dfcf98d59caa2a26a5710",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765438918,
      "headline": "Stocks making the biggest moves premarket: Oracle, Oxford Industries, Adobe, Gemini Space Station & more",
      "id": 137759188,
      "image": "https://image.cnbcfm.com/api/v1/image/108113602-1741633582507-gettyimages-2204393291-_73a5201_8iunpbee.jpeg?v=1765456260&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "These are the stocks posting the largest moves in early trading. ",
      "url": "https://finnhub.io/api/news?id=acb3d6f743f2fe1124fa13f9b32b4b64e62f2e1b326dfcf98d59caa2a26a5710"
    }
  },
  {
    "ts": null,
    "headline": "Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly",
    "summary": "Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight loss medicines near market entry.",
    "url": "https://finnhub.io/api/news?id=f51c55eaad987bfbdde92a4861cd383e0f8cc9db88e505a213c9f2da47e6edcc",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765438786,
      "headline": "Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly",
      "id": 137759190,
      "image": "https://image.cnbcfm.com/api/v1/image/108198080-1757684463529-gettyimages-2177418373-20240909_cpupo_remedios_0832.jpeg?v=1757684482&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight loss medicines near market entry.",
      "url": "https://finnhub.io/api/news?id=f51c55eaad987bfbdde92a4861cd383e0f8cc9db88e505a213c9f2da47e6edcc"
    }
  },
  {
    "ts": null,
    "headline": "Prolynx banks $70M for longer-lasting obesity drugs",
    "summary": "Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can be administered monthly or quarterly.",
    "url": "https://finnhub.io/api/news?id=98ca15626ce2aca6ecf6a7d358e88fc2a37f88f6caa5407e7640ca0a45729fe4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765436400,
      "headline": "Prolynx banks $70M for longer-lasting obesity drugs",
      "id": 137757884,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can be administered monthly or quarterly.",
      "url": "https://finnhub.io/api/news?id=98ca15626ce2aca6ecf6a7d358e88fc2a37f88f6caa5407e7640ca0a45729fe4"
    }
  },
  {
    "ts": null,
    "headline": "Microsoft, Broadcom, Lilly, and Other Stocks That Meet This Pro’s Definition of ‘Quality’",
    "summary": "Tom Hancock, a portfolio manager at GMO, favors companies that consistently earn a high return on capital and reinvest in the business.",
    "url": "https://finnhub.io/api/news?id=ee0998ec647cad453c57eb3fd506deaaba4b54b18f1fc18a5336ba3f08dc6593",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765436400,
      "headline": "Microsoft, Broadcom, Lilly, and Other Stocks That Meet This Pro’s Definition of ‘Quality’",
      "id": 137755713,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Tom Hancock, a portfolio manager at GMO, favors companies that consistently earn a high return on capital and reinvest in the business.",
      "url": "https://finnhub.io/api/news?id=ee0998ec647cad453c57eb3fd506deaaba4b54b18f1fc18a5336ba3f08dc6593"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial",
    "summary": "The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.",
    "url": "https://finnhub.io/api/news?id=9da6dbc3a6075d3881008361ba971b15dff685655146599c0f9dc579c7668f84",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765435525,
      "headline": "Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  ",
      "id": 137759192,
      "image": "https://image.cnbcfm.com/api/v1/image/108230176-1764603822722-108230176-17637559702025-11-21t201158z_1546648356_rc261iafo6zz_rtrmadp_0_lilly-stocks.jpg?v=1764603832&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill. ",
      "url": "https://finnhub.io/api/news?id=9da6dbc3a6075d3881008361ba971b15dff685655146599c0f9dc579c7668f84"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Is Not Cheap [Rating Downgrade]",
    "summary": "Novo Nordisk faces price weakness, declining earnings forecasts, stagnant margins, and GLP-1 growth challenges. Read why NVO stock is downgraded to hold.",
    "url": "https://finnhub.io/api/news?id=da3507ccb6bfc5160c07ca00eda3ba2585f2ab425e3099c835b0884bfb0e9b2f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765434213,
      "headline": "Novo Nordisk Is Not Cheap [Rating Downgrade]",
      "id": 137756505,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305436/image_2158305436.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk faces price weakness, declining earnings forecasts, stagnant margins, and GLP-1 growth challenges. Read why NVO stock is downgraded to hold.",
      "url": "https://finnhub.io/api/news?id=da3507ccb6bfc5160c07ca00eda3ba2585f2ab425e3099c835b0884bfb0e9b2f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Is Trading as If Obesity Drug Craze Never Happened",
    "summary": "The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a weight-loss treatment in 2021.  “When I look at it right now, organically, their pipeline doesn’t convince me that this situation is manageable,” said Paul Major, a portfolio manager at Bellevue Asset Management.  Novo bulls are hoping that pending approvals of a higher-dose Wegovy shot and an oral version of the drug will turn things around and boost the company’s position against rival Eli Lilly & Co. Novo has sought approval of the stronger injectable version of Wegovy in the US under a priority voucher, which will speed review.",
    "url": "https://finnhub.io/api/news?id=89ee3d98253ab4fae9b6d47f097baaeb6f49e2e74121f26aafe66cf106fad9ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765433700,
      "headline": "Novo Nordisk Is Trading as If Obesity Drug Craze Never Happened",
      "id": 137755832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a weight-loss treatment in 2021.  “When I look at it right now, organically, their pipeline doesn’t convince me that this situation is manageable,” said Paul Major, a portfolio manager at Bellevue Asset Management.  Novo bulls are hoping that pending approvals of a higher-dose Wegovy shot and an oral version of the drug will turn things around and boost the company’s position against rival Eli Lilly & Co. Novo has sought approval of the stronger injectable version of Wegovy in the US under a priority voucher, which will speed review.",
      "url": "https://finnhub.io/api/news?id=89ee3d98253ab4fae9b6d47f097baaeb6f49e2e74121f26aafe66cf106fad9ed"
    }
  },
  {
    "ts": null,
    "headline": "Did Eli Lilly's (LLY) US$6 Billion Alabama Bet on Orforglipron Just Shift Its Investment Narrative?",
    "summary": "Eli Lilly and Company recently announced plans to invest more than US$6.00 billion in a new Huntsville, Alabama API facility that will produce small‑molecule and peptide medicines, including its oral GLP‑1 obesity candidate orforglipron, with construction slated to begin in 2026 and completion targeted for 2032. Alongside this large U.S. manufacturing build‑out, Lilly is advancing Jaypirca in leukemia with Phase 3 data and expanded FDA approval, underscoring how obesity and oncology...",
    "url": "https://finnhub.io/api/news?id=2e4e911a14860413f703fd30d04c32bcc34ed4ea7070c6cbe38295b6d449111c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765429838,
      "headline": "Did Eli Lilly's (LLY) US$6 Billion Alabama Bet on Orforglipron Just Shift Its Investment Narrative?",
      "id": 137755833,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company recently announced plans to invest more than US$6.00 billion in a new Huntsville, Alabama API facility that will produce small‑molecule and peptide medicines, including its oral GLP‑1 obesity candidate orforglipron, with construction slated to begin in 2026 and completion targeted for 2032. Alongside this large U.S. manufacturing build‑out, Lilly is advancing Jaypirca in leukemia with Phase 3 data and expanded FDA approval, underscoring how obesity and oncology...",
      "url": "https://finnhub.io/api/news?id=2e4e911a14860413f703fd30d04c32bcc34ed4ea7070c6cbe38295b6d449111c"
    }
  }
]